KR20190130643A - 생물학적 활성 분자의 지속적인 전달을 위한 미네랄 코팅된 마이크로입자 - Google Patents

생물학적 활성 분자의 지속적인 전달을 위한 미네랄 코팅된 마이크로입자 Download PDF

Info

Publication number
KR20190130643A
KR20190130643A KR1020197032235A KR20197032235A KR20190130643A KR 20190130643 A KR20190130643 A KR 20190130643A KR 1020197032235 A KR1020197032235 A KR 1020197032235A KR 20197032235 A KR20197032235 A KR 20197032235A KR 20190130643 A KR20190130643 A KR 20190130643A
Authority
KR
South Korea
Prior art keywords
mineral
active agent
antagonists
mineral coating
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197032235A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 머피
안나 클레멘츠
코니 체임벌린
레이 밴더비
Original Assignee
위스콘신 얼럼나이 리서어치 화운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위스콘신 얼럼나이 리서어치 화운데이션 filed Critical 위스콘신 얼럼나이 리서어치 화운데이션
Publication of KR20190130643A publication Critical patent/KR20190130643A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197032235A 2017-04-03 2018-04-03 생물학적 활성 분자의 지속적인 전달을 위한 미네랄 코팅된 마이크로입자 Ceased KR20190130643A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480710P 2017-04-03 2017-04-03
US62/480,710 2017-04-03
PCT/US2018/025913 WO2018187344A1 (en) 2017-04-03 2018-04-03 Mineral coated microparticles for sustained delivery of biologically active molecules

Publications (1)

Publication Number Publication Date
KR20190130643A true KR20190130643A (ko) 2019-11-22

Family

ID=63712804

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032235A Ceased KR20190130643A (ko) 2017-04-03 2018-04-03 생물학적 활성 분자의 지속적인 전달을 위한 미네랄 코팅된 마이크로입자

Country Status (10)

Country Link
US (1) US12465654B2 (enExample)
EP (1) EP3606512A4 (enExample)
JP (1) JP7170031B2 (enExample)
KR (1) KR20190130643A (enExample)
CN (1) CN110691588A (enExample)
AU (1) AU2018249816B2 (enExample)
BR (1) BR112019020373A2 (enExample)
CA (1) CA3058802A1 (enExample)
IL (1) IL269607A (enExample)
WO (1) WO2018187344A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3606512A4 (en) 2017-04-03 2021-01-13 Wisconsin Alumni Research Foundation MINERAL COATED MICROPARTICLES INTENDED FOR THE PROLONGED DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES
WO2022051247A1 (en) * 2020-09-01 2022-03-10 Dianomi Therapeutics, Inc. Methods for treating or preventing inflammatory events
DE102020129648A1 (de) * 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung
CN114917364A (zh) * 2022-05-12 2022-08-19 云南大学附属医院 一种携IL-8和Anakinra双配体靶向纳米微泡的制备方法
WO2024102801A2 (en) * 2022-11-09 2024-05-16 Wisconsin Alumni Research Foundation Mineral-coated iron oxide microparticles and use of same including use for immunomodulation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
JP2003212756A (ja) * 2002-01-21 2003-07-30 Olympus Optical Co Ltd 薬剤徐放剤
CA2568352C (en) * 2004-06-04 2011-09-13 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US7655758B2 (en) * 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
AU2006290870B2 (en) * 2005-09-14 2013-02-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
JPWO2008041704A1 (ja) 2006-10-02 2010-02-04 独立行政法人物質・材料研究機構 徐放性製剤
US20100143439A1 (en) * 2007-04-16 2010-06-10 University Of Toledo Hybrid Biomimetic Particles, Methods of Making Same and Uses Therefor
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US20090111763A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable polymeric particles for bone augmentation and methods of preparing and using the same
CN105688276A (zh) 2008-02-29 2016-06-22 史密夫和内修有限公司 用于生物医学应用的梯度涂层
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
JP2012503673A (ja) * 2008-09-25 2012-02-09 ティッシュ リジェネレーション システムズ インコーポレイテッド ミネラルコーティングされたマイクロスフェア
US20160017368A1 (en) 2013-02-19 2016-01-21 Wisconsin Alumni Research Foundation Inorganic coatings for the enhancement of chemical transfection
WO2016141242A1 (en) 2015-03-03 2016-09-09 Tissue Regeneration Systems, Inc. Coating scaffolds
US10780054B2 (en) 2015-04-17 2020-09-22 Curevac Real Estate Gmbh Lyophilization of RNA
EP3606512A4 (en) 2017-04-03 2021-01-13 Wisconsin Alumni Research Foundation MINERAL COATED MICROPARTICLES INTENDED FOR THE PROLONGED DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES
JP2020526515A (ja) 2017-07-05 2020-08-31 ウィスコンシン・アルムナイ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子
US11628227B2 (en) 2017-07-05 2023-04-18 Wisconsin Alumni Research Foundation Mineral coated microparticles for gene delivery in chronic wound therapy
EP3556728A1 (en) 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
US20190358344A1 (en) 2018-05-23 2019-11-28 Dianomi Therapeutics, Inc. Mineral coated microparticles for sustained delivery of steroids
WO2023086816A1 (en) 2021-11-09 2023-05-19 Wisconsin Alumni Research Foundation Mineral-coated substrates for stabilization of rna-based therapeutic compositions

Also Published As

Publication number Publication date
IL269607A (en) 2019-11-28
JP2020513033A (ja) 2020-04-30
WO2018187344A1 (en) 2018-10-11
CA3058802A1 (en) 2018-10-11
EP3606512A4 (en) 2021-01-13
EP3606512A1 (en) 2020-02-12
BR112019020373A2 (pt) 2020-04-28
AU2018249816A1 (en) 2019-10-17
US12465654B2 (en) 2025-11-11
US20200164087A1 (en) 2020-05-28
CN110691588A (zh) 2020-01-14
AU2018249816B2 (en) 2025-04-17
JP7170031B2 (ja) 2022-11-11

Similar Documents

Publication Publication Date Title
US12465654B2 (en) Mineral coated microparticles for sustained delivery of biologically active molecules
Gao et al. Hydrogel–metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis
Nich et al. Macrophages—key cells in the response to wear debris from joint replacements
ES2363162T3 (es) Composicones y procedimientos para el tratamiento de trastornos fibróticos.
CN107847556B (zh) Prg4作为抗炎剂的应用
AU2014346051B2 (en) Use of IL-22 dimers in manufacture of medicaments for treating pancreatitis
Afsar et al. The future of IL-1 targeting in kidney disease
US11779542B2 (en) Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
JP2016511747A (ja) ナノ粒子表面結合に基づく薬物の組織への送達
US20250032677A1 (en) Compositions and methods for modulating wound healing and regeneration
WO2019213686A1 (en) Therapeutic compositions and uses therefor
JP2020511415A (ja) 線維症の処置のためのインターフェロン−ラムダの医学的使用
US12178849B2 (en) Autoimmune disease treatment with chemokine-loaded alginate microparticles
CN1287852C (zh) 含有midkine或其抑制剂作为活性成分的药剂
Wang et al. A cationic hydrogel with anti-IL-17A-specific nanobodies for rheumatoid arthritis treatment via inhibition of inflammatory activities of neutrophils
JP2015524402A (ja) 創傷治療用の薬剤
HK40014557A (en) Mineral coated microparticles for sustained delivery of biologically active molecules
WO2022051247A1 (en) Methods for treating or preventing inflammatory events
Na et al. Formulation and evaluation of VCAM-1-Targeted methotrexate lipid nanoparticles for rheumatoid arthritis therapy
Wang et al. Exploring the multi-repair effects of advanced biomimetic rapamycin nanoparticles on cerebral ischemia-reperfusion injury
Shao et al. Metal–Organic Framework-Integrated Nanoplatform Orchestrates Osteochondral-Synovial Homeostasis for Osteoarthritis Therapy
Hao et al. Drug-free mesenchymal stem cell-mimicking nanodecoys suppress inflammation and attenuate new bone formation in ankylosing spondylitis
Ruan et al. Effects of synovial macrophages
김도연 The effect of ZnO-Loaded PCL fibers on promoting bone healing in the elderly mouse through the modulation of NETosis
JP2003201253A (ja) 臓器移植後拒絶反応としての移植後動脈硬化症の予防及び／又は治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191030

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210402

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230329

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230602

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230329

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I